Experience of orthotopic liver transplantation in 11 patients with liver cirrhosis from Korea: medical factors affecting outcome.
Orthotopic liver transplantation (OLT) has evolved to become a standard treatment of choice for end-stage liver diseases. The present study was performed to evaluate the peri-operative medical factors affecting transplantation outcome and to determine if patients with type B viral cirrhosis were acceptable for OLT. A total of 11 patients with end-stage cirrhosis, who have received OLT in Kangnam St. Mary's Hospital since May 1993, included 8 HBV-related cases, 1 Hepatitis C Virus (HCV)-related case, and 2 non-B, non-C cases. One-year cumulative survival rate by Kaplan-Meier method was 43.7%. Factors significantly associated with 1-year survival of the recipients during pre-OLT period were performance status and modified Pugh-Child score (p=0.015 and p=0.015, respectively). Among those 4 patients who lived longer than 1 year, 3 of 4 patients with HBsAg-positive had no HBV re-infection with our protocol. These results suggest that, to improve the outcome of OLT in cirrhosis patients, transplantation should be performed in the stage when patients maintain better performance and hepatic functional reserve during the end-stage of liver cirrhosis. In addition, patients with cirrhosis caused by HBV infection may be indicated for OLT, because HBV re-infection is preventable effectively with a high-dose hepatitis B immunoglobulin protocol.
Department of Internal Medicine, WHO Collaborating Centre for Reference and Research on Viral Hepatitis in Korea, The Catholic University of Korea, Seoul.
J Y
JY
Choi
Y M
YM
Park
B H
BH
Byun
T Y
TY
Kim
S K
SK
Yoon
K W
KW
Chung
H S
HS
Sun
D H
DH
Park
B S
BS
Kim
D G
DG
Kim
I C
IC
Kim
D000293:Adolescent; D000328:Adult; D016174:Hepacivirus; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D006515:Hepatitis B virus; D006801:Humans; D008103:Liver Cirrhosis / Q000601:surgery* / Q000821:virology; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D016896:Treatment Outcome
D006514:Hepatitis B Surface Antigens